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ABSTRACT
Purpose Thromboembolic complications remain a limi-
tation of flow diverting stents. We hypothesize that phos-
phorilcholine surface modified flow diverters (Pipeline 
Flex with Shield Technology, sPED) would have less acute 
thrombus formation on the device surface compared 
with the classic Pipeline Embolization device (cPED).
Methods Elastase-induced aneurysms were created 
in 40 rabbits and randomly assigned to receive cPED or 
sPED devices with and without dual antiplatelet therapy 
(DAPT) (four groups, n=10/group). Angioplasty was 
performed to enhance apposition and create intimal 
injury for a pro-thrombotic environment. Both before 
and after angioplasty, the flow diverter was imaged with 
intravascular optical coherence tomography. The outcome 
measure was the number of predefined segments along 
the implant relative to the location of the aneurysm with 
a minimum of 0 (no clot formation) and maximum of 3 
(all segments with thrombus). Clot formation over the 
device at ostia of branch arteries was assessed as either 
present or absent.
Results Following angioplasty, the number of flow 
diverter segments with clots was significantly associated 
with the flow diverter (p<0.0001), but not with DAPT 
(p=0.3872) or aneurysm neck size (p=0.8555). The 
incidence rate for clots with cPED was 1.72 times 
more than with sPED. The clots on the flow diverter 
at the location corresponding to side branch ostia 
was significantly lower with sPED than with cPED (OR 
0.180; 95% CI 0.044 to 0.734; p=0.0168), but was not 
associated with DAPT (p=0.3198).
Conclusion In the rabbit model, phosphorilcholine 
surface modified flow diverters are associated with less 
thrombus formation on the surface of the device.
InTRoduCTIon
In the past 10 years, flow diverters (FDs) have been 
successfully used to treat large and giant unruptured 
intracranial aneurysms, primarily located in the 
anterior circulation.1 2 A recently published study 
demonstrated a high and gradually increasing aneu-
rysm occlusion rate (95.2%) over a 5-year follow-up 
period3; however, in multiple large studies, major 
ipsilateral ischemic strokes have been reported with 
a range between 1.6% and 4.3%.1 2 Prevention of 
thromboembolic events is complicated by variable 
response to antiplatelet therapy, unpredictable 
patient compliance with medication, potential drug 
interactions, and the presence of comorbidities. 
These factors may all contribute to the formation 
of thrombi on the surface of the FDs during the 
procedure, which eventually serves as a source of 
emboli.4 Depending on the eloquence of affected 
brain parenchyma, the patient may suffer significant 
neurological deficits. Although the risk of ischemic 
events gradually decreases over time after device 
implant, it may be present until the endothelializa-
tion is completed and the FD is fully incorporated 
into the remodeled artery.
In an effort to decrease the periprocedural 
thromboembolic complications, phosphorilcholine 
(PC) coated stents were developed and assessed in 
cardiology.5 However, this experience cannot be 
fully translated to neuroendovascular procedures 
due to differences in vessel size (parent vessel and 
side branches), hemodynamic environment, and 
overall device engineering.
Recently, a surface modified FD that covalently 
bonds 3 nm of PC to the braid wires has been 
introduced (Pipeline Flex with Shield Technology, 
Medtronic Neurovascular, Irvine, California, 
USA).6 We hypothesized that the Pipeline Flex with 
Shield Technology (sPED) would have less thrombus 
formation on the surface of the device compared 
with the classic Pipeline device (cPED). Further-
more, we assessed the consequences of angioplasty 
(after FD implant) on acute clot formation and 
evaluated how successfully this unwanted compli-
cation could be eliminated by using the Shield 
device. Our outcome measure was clot formation 
observed in vivo using optical coherence tomog-
raphy (OCT) at three locations along the surface 
of the FD (figure 1). Clot formation was assessed as 
present (1) or absent (0) at each of these locations 
and summed for each animal, giving a maximum 
score of 3 and a minimum score of 0. Additionally, 
clot formation at the origin of covered side branch 
arteries was scored as a binary output (present or 
absent).
MATeRIAlS And MeThodS
Aneurysm creation and study design
After Institutional Animal Care and Use Committee 
approval, elastase-induced aneurysms were created 
in 40 New Zealand white rabbits at the origin of 
the right common carotid artery as previously 
described.7 A minimum of 3 weeks after creation, 
the aneurysms were screened via non-invasive 
intra-arterial digital subtraction angiography (DSA)8 
and randomized to one of the following treatment 
groups: (1) cPED with animal on dual antiplatelet 
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therapy (DAPT); (2) sPED with DAPT; (3) cPED without DAPT; 
and (4) sPED without DAPT. Animals assigned to DAPT received 
oral aspirin (10 mg/kg) and clopidogrel (10 mg/kg) beginning 5 
days prior to FD implant and continued for the duration of the 
study.
Flow diverter implant and oCT imaging
All procedures were performed under general anesthesia. First, 
the animals were pre-anesthetized by a subcuticular injection of 
atropine (0.01 mg/kg), followed by an intramuscular injection of 
ketamine (35 mg/kg) and xylazine (5 mg/kg) for anesthesia induc-
tion. Mechanical ventilation was maintained with 1–3%  isoflu-
rane. Vitals were continuously monitored and respiration rate, 
oxygen saturation, end-tidal CO2, heart rate, and temperature 
were recorded.
The right common femoral artery was surgically exposed and 
a 6Fr introducer sheath was inserted. A Navien 072 was used 
to navigate the FD to the right subclavian artery. Both devices 
were sized based on the diameter of the brachiocephalic trunk 
proximal to the aneurysm and ranged from 3.75 to 4.5 mm. All 
devices were 16 mm in length. The device was deployed under 
fluoroscopic guidance and implanted once complete coverage of 
the aneurysm neck was documented. Angioplasty was performed 
on all devices (HyperGlide 4 mm x 10 mm) to optimize appo-
sition and create a more aggressive environment for clot forma-
tion.
Before and after angioplasty, OCT imaging (Dragonfly Cath-
eter, St Jude Medical, Westford, Massachusetts, USA) was 
performed in order to quantify the clot formation on the surface 
of the FD. The OCT images were acquired with a 10 mm/s pull-
back speed through 54 mm length, generating 540 frames/pull-
back. For sufficient blood clearance, iodinated contrast (Omni-
paque 240, GE Healthcare, Malborough, Massachusetts, USA) 
was administered by a power injector at a flow rate of 4 mL/s for 
4 s. In each case all 540 images acquired pre- and post-angioplasty 
were analyzed in a blinded fashion at three segments (distal to 
the vertebral artery (DV); distal to the aneurysm but proximal 
to the vertebral artery (DA&PV); and proximal to the aneurysm 
(PA); figure 1). The number of segments with clots (count vari-
able) was the outcome variable of interest. Thus, there could 
be a maximum of three segments and a minimum of zero. In 
addition, clot formation at the aneurysm neck and at locations 
corresponding to side branches—namely the internal thoracic, 
vertebral, and cervical arteries—were quantified for presence/
absence (binary variable). Aspirin reaction units (ARU) and 
P2Y12 reaction units (PRU) were measured prior to random-
ization to treatment group and at the time of implant with the 
VerifyNow instrument (Accriva, San Diego, California, USA). 
Aneurysm occlusion was assessed prior to euthanasia at 30 days 
on a previously described 4-point scale.9
Statistical methods
For the outcome variable of interest (ie, number of segments 
with clots), Poisson regression that is appropriate for the count 
variable was used for modeling. The independent variables of 
interest were the FD (sPED vs cPED), DAPT (yes or no), and 
the aneurysm neck size (mm). A χ2 goodness-of-fit test was 
used to assess if the Poisson model form fit the data. In order 
to assess if clots formed at the aneurysm neck and at the loca-
tion corresponding to side branches were associated with the 
independent variables, multivariable logistic regression models 
that were appropriate for binary data were used. All multivari-
able logistic regression models employed Firth’s bias correction 
and Hosmer–Lemeshow goodness-of-fit were assessed. For the 
cohort that underwent DAPT, the differences in ARU and PRU 
from time of implant to baseline were quantified. Shapiro–Wilk’s 
test was used to test for normality and either a paired t-test or 
Wilcoxon signed rank sum test was used to analyze the effective-
ness of DAPT.
ReSulTS
Aneurysm and parent vessel characteristics
Randomization was effective, and there were no differences in 
baseline aneurysm characteristics (table 1). The aneurysm occlu-
sion rates at 30 days across the four groups were not different 
(p=0.8512, Kruskal–Wallis test) and were independent of 
DAPT administration and device type. In each group at 30-day 
follow-up imaging, half of the aneurysms were either completely 
occluded or had a small neck remnant, and the remaining half 
continued to have filling of the aneurysm dome.
effectiveness of dAPT
For the cohort that received DAPT, the difference in PRU 
prior to and 5 days after DAPT was initiated did not satisfy 
the normality assumption (p=0.0014). The Wilcoxon signed 
rank sum test indicated that the PRU 5 days after DAPT was 
significantly lower than before administration of clopidogrel 
(median difference −164 (Q1, Q3 −170, –148), p=0.0039). At 
the time of implant, animals receiving DAPT had a significantly 
lower PRU (median 67 vs 251, respectively; p<0.0001, unpaired 
two-tailed t-test after satisfying normality test) than those not 
receiving antiplatelet medications. For the cohort that under-
went DAPT, the difference in ARU before and 5 days after 
administering DAPT marginally satisfied the normality assump-
tion (p=0.0810). The paired t-test indicated that the ARU was 
lower 5 days after DAPT than at baseline (mean±SD difference 
−6.833±11.72), but was not significant (p=0.2126). ARU 
values were not different between animals administered aspirin 
Figure 1 Anatomical locations for scoring thrombus formation. 
Summation of the number of locations with clot appreciated on the 
surface of the device resulting in scores ranging from 0 to 3. DV, distal 
to vertebral artery; DA&PV, distal to the aneurysm and proximal to the 
vertebral artery; PA, proximal to aneurysm.
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and those not given aspirin (p=0.75, unpaired two-tailed Mann–
Whitney test).
number of Fd segments with clots
Prior to angioplasty, the number of FD segments with clots 
quantified using OCT were not associated with the FD 
(p=0.8279), DAPT (p=0.5177), or neck size (p=0.4363). χ2 
goodness-of-fit showed that the Poisson model form fit the 
data (p=0.999). After angioplasty the number of FD segments 
with clots quantified using OCT (figure 2A) was significantly 
associated with the FD (p<0.0001), but not with DAPT 
(p=0.3872) or neck size (p=0.8555). When neck size and the 
use of DAPT are held constant, the incidence rate for clots 
with cPED was 1.72 times more than that of sPED. χ2 good-
ness-of-fit showed that the Poisson model form fit the data 
(p=0.998).
Clots on Fd at the location corresponding to side branches
Prior to angioplasty, the clots on the FD at the location corre-
sponding to side branches were not associated with the FD 
(p=0.3169), DAPT (p=0.7009), or neck size (p=0.9115). 
Hosmer–Lemeshow goodness-of-fit was satisfied (p=0.1798). 
Post angioplasty, the clots on the FD at the location corre-
sponding to side branches (figure 2B) were significantly lower 
with sPED than with cPED (OR 0.180; 95% CI 0.044 to 0.734; 
p=0.0168), but were not associated with DAPT (p=0.3198) or 
neck size (p=0.6610). Hosmer–Lemeshow goodness-of-fit was 
satisfied (p=0.3119).
Clots on Fd at the location corresponding to aneurysm neck
Prior to angioplasty, the clots on the FD at the location corre-
sponding to the aneurysm neck were not associated with the 
Table 1 Baseline characteristics of the aneurysm, parent vessel dimensions, platelet function, and the devices deployed. 
cPed sPed
p Valueno dAPT dAPT no dAPT dAPT
Aneurysm neck size (mm) 4.1±1.3 3.8±0.7 3.9±1.0 4.3±1.8 0.78
Aneurysm width (mm) 3.8±0.9 3.3±0.8 3.8±0.9 3.4±1.0 0.51
Aneurysm height (mm) 7.7±2.2 6.3±1.2 7.6±2.5 7.7±2.3 0.33
Parent vessel diameter proximal to aneurysm (mm) 3.7±0.3 4.0±0.6 3.6±0.4 3.9±0.4 0.18
Parent vessel diameter distal to aneurysm (mm) 3.7±0.8 3.6±0.4 3.5±0.5 3.9±0.8 0.58
Subclavian artery diameter (mm) 2.2±0.2 2.3±0.3 2.2±0.3 2.4±0.4 0.30
PRU 261±48 56±26 249±52 84±26 <0.0001
ARU 661±6 642±43 636±57 657±12 0.90
Device diameter (mm) 4.0 4.0 4.0 4.125 0.58
Proximal landing zone NS
   Innominate artery 9 9 9 9
  Herniation into aorta 1 1 1 1
All quantities expressed as mean±SD, except device diameters (median) and proximal landing zone (number of animals).
ARU, aspirin reaction units; cPED, classic Pipeline Embolization Device; DAPT, dual antiplatelet therapy; PRU, P2Y12 reaction units; sPED, Pipeline Flex with Shield Technology.
Figure 2 Frequency of clot scores in each group. (A) Immediately after angioplasty during the implant procedure there is a significant reduction 
in the number of locations with visible clot on optical coherence tomography (OCT) for the Shield Pipeline Embolization Device (sPED) and no 
appreciable difference as a function of dual antiplatelet treatment (DAPT). (B) Immediately after angioplasty following device implantation the 
frequency of clots forming along the surface of the device covering the ostia of side branch arteries (SB) is reduced with the new generation flow 
diverter (sPED) and did not change as a function of DAPT.
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FD (p=0.4399), DAPT (p=0.5537), or neck size (p=0.9651). 
Hosmer–Lemeshow goodness-of-fit was satisfied (p=0.9440). 
Post angioplasty, the clots on the FD at the location corre-
sponding to the aneurysm neck were not associated with the 
FD (p=0.9374), DAPT (p=0.9263), or neck size (p=0.6546). 
Hosmer–Lemeshow goodness-of-fit was satisfied (p=0.7252).
dISCuSSIon
This animal study deployed OCT in order to identify small but 
potentially harmful thrombi on the surface of flow diverters. The 
identified thrombi size ranged from 0.4 mm to 1.2 mm. Despite 
DSA failing to reveal clots on the surface of the FD (figure 3), 
OCT indicated the presence and exact locations of thrombi, 
potentially serving as guidance for more targeted treatment. It 
has further been shown that DSA fails to depict FD malapposi-
tion in rabbit models compared with histological evaluation.10 
The usefulness of OCT in detecting acutely formed micro-
thrombi11 and stent apposition12 has been extensively studied 
in cardiology, but currently there is no dedicated neurovascular 
OCT system, representing an opportunity for technology devel-
opment. Besides the higher spatial resolution of OCT, the ability 
to assess the inner lumen of the vessel along with the implanted 
FD in a 360o view provides additional advantages for detailed 
analysis.13 14 In contrast, the two-dimensional view of DSA can 
lead to false-negative identification of microthrombi. In general, 
the morphology of the clot identified by OCT was an irregular 
layer that could be observed in multiple slices without significant 
luminal narrowing. Importantly, microthrombi were frequently 
observed at the ostia of small side branches, representing an 
important potential source for thromboembolic complications.
On the initial OCT, immediately following device implant, 
there was no difference in clot formation between the cPED and 
sPED groups and, more interestingly, it appeared that DAPT did 
not have any effect on preventing clot formation during any of 
the different stages of the procedure. However, by performing 
angioplasty after device implant and exposing the thrombogenic 
subendothelial layer of the vessel, sPED showed significantly 
fewer newly formed thrombi than cPED, supporting our hypoth-
esis that PC surface modified FDs can be protective against acute 
clot formation, especially after angioplasty. A more profound 
result was the statistically significant reduction of microthombi 
at the FD covered orifice of small branch arteries when sPED 
was used. Despite a reduction of thrombi along the luminal 
surface of the device, sPED did not alter the presence of thrombi 
acutely at the location of the aneurysm or aneurysm occlusion 
rates on 30-day follow-up angiography.
These data may lead to the conclusion that, in this 
model, avoiding angioplasty is critical for the prevention of 
Figure 3 Following the implant and angioplasty of a classic Pipeline embolization device in an animal not receiving dual antiplatelet therapy, 
significant thrombus accumulation is seen distal to the aneurysm (A, arrow) that is not observed on standard digital subtraction angiography (B). In 
another animal of the same group, thrombus developed over a covered side branch (C, arrow) without filling deficit on angiography (D). Angiography 
shows a filling deficit downstream from the device (D, arrow).
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microthrombi along the surface of the device. However, our 
study design cannot confirm this conclusion since the pre-angio-
plasty OCT was performed immediately following FD deploy-
ment whereas the post-angioplasty delayed imaging by more 
than 30 min. Although angioplasty was specifically deployed 
to create an aggressive but clinically relevant pro-thrombotic 
environment to assess the benefit of the modified FD, time 
from implant may have also contributed to platelet aggre-
gates. Our study design did not include a no angioplasty group 
with delayed OCT acquisition, since this would have doubled 
the number of animals required without contributing signif-
icant information to testing the stated hypothesis. Notably, 
malapposition of FDs is clearly underappreciated by existing 
imaging systems and critical for aneurysm occlusion following 
FD placement.10 Numerous techniques are used for improving 
FD apposition such as gentle manipulation with the delivery 
microcatheter, intermediate distal access catheter,15 balloon 
angioplasty,15 16 or the use of self-expanding stents to pin the 
FD.17 We deployed angioplasty since, of these techniques, it 
offers reproducibility.
Platelet function testing and titration of DAPT for indi-
vidual patients has been advocated to reduce thromboem-
bolic or bleeding complications.18–20 However, in both coro-
nary stenting21 and neurointerventional treatment of aneu-
rysms,22 23 pre-procedural platelet aggregation testing has 
failed to demonstrate benefit in clinical outcomes. Due to the 
variability of patient response to standard DAPT regimens, 
there is a need for endovascular devices with reduced throm-
bogenicity that can produce a predictable platelet response. 
Our study shows that the sPED technology is an important 
development towards this goal.
Our study has limitations. Although the rabbit model is 
well established for studying antiplatelet effects of clopido-
grel and aspirin,24–28 these animals had a standard labora-
tory diet, were medicated on a precise schedule, and did not 
have comorbidities. Therefore, the response of the model to 
DAPT may not translate to clinical populations. Due to the 
location of the implant in the subclavian artery, we could 
not correlate thrombus formation observed on OCT with 
clinical sequelae. Despite low porosity implants in small 
diameter arteries, we did not observe device thrombosis 
in the absence of DAPT. Finally, we did not perform acute 
histology following the implant procedure, as this would not 
allow assessment of 30-day aneurysm occlusion and patency 
of parent and branch arteries. Although we cannot confirm 
with histology the OCT findings, we relied on the exten-
sive literature for appearance of thrombus on endoluminal 
devices using OCT.12
Contributors Study design: MM, JMW, MJg ASP. Data acquisition: MM, FC, 
ETl, RMK, OWB, TT. literature research: MM, MJg, SV, ASP. Data analysis and 
interpretation: MM, SV, MJg, ASP. Manuscript preparation: MM MJg, SV. Revision 
of manuscript for important intellectual content: ASP. Approval of final version of 
manuscript: all authors.
Funding This work was supported by Medtronic neurovascular. The content is 
solely the responsibility of the authors, and does not represent the official views of 
Medtronic.
Competing interests MM, FC, ETl, RMK, OWB, TT, SV: none. JMW: Employed 
by Medtronic neurovascular. MJg: has been a consultant on a fee-per-hour basis 
for Codman neurovascular, InneuroCo and Stryker neurovascular; holds stock 
in InneuroCo; and has received research support from the national Institutes 
of health (nIh), CereVasc llC, Codman neurovascular, gentuity, Microvention, 
Medtronic neurovascular, neuravi, Philips healthcare, InneuroCo, Rapid Medical, 
Stryker neurovascular, and the Wyss Institute. ASP: has been a consultant on 
a fee-per-hour basis for Medtronic neurovascular and Stryker neurovascular; 
and has received research grants from Medtronic neurovascular and Stryker 
neurovascular.
Provenance and peer review not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution non Commercial (CC BY-nC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1 Kallmes DF, Brinjikji W, Cekirge S, et al. Safety and efficacy of the pipeline 
embolization device for treatment of intracranial aneurysms: a pooled analysis of 3 
large studies. J Neurosurg 2016:1–6.
 2 Wakhloo AK, lylyk P, de Vries J, et al. Surpass flow diverter in the treatment 
of intracranial aneurysms: a prospective multicenter study. Am J Neuroradiol 
2015;36:98–107.
 3 Becske T, Brinjikji W, Potts MB, et al. long-Term clinical and angiographic outcomes 
following pipeline embolization device treatment of complex internal carotid artery 
aneurysms: five-year results of the pipeline for uncoilable or failed aneurysms trial. 
Neurosurgery 2017;80:40–8.
 4 Safain Mg, Roguski M, heller RS, et al. Flow diverter therapy with the pipeline 
embolization device is associated with an elevated rate of delayed fluid-attenuated 
inversion recovery lesions. Stroke 2016;47:789–97.
 5 Rodriguez AE, Rodriguez Alemparte M, Fernandez Pereira C, et al. latin American 
randomized trial of balloon angioplasty versus coronary stenting in diabetic patients 
with small vessel reference size (latin American small vessel [lASMAl II] Trial): 
immediate and long-term results. Am Heart J 2005;150:188.
 6 hagen MW, girdhar g, Wainwright J, et al. Thrombogenicity of flow diverters 
in an ex vivo shunt model: effect of phosphorylcholine surface modification. J 
Neurointerv Surg 2016: Published Online First: 31 October 2016. doi: 10.1136/
neurintsurg-2016-012612.
 7 Altes TA, Cloft hJ, Short Jg, et al. 1999 ARRS Executive Council award. creation of 
saccular aneurysms in the rabbit: a model suitable for testing endovascular devices. 
American Roentgen Ray Society. Am J Roentgenol 2000;174:349–54.
 8 Miskolczi l, nemes B, Cesar l, et al. Contrast injection via the central artery of the 
left ear in rabbits: a new technique to simplify follow-up studies. Am J Neuroradiol 
2005;26:1964–6.
 9 Darsaut TE, Bing F, Salazkin I, et al. Flow diverters can occlude aneurysms 
and preserve arterial branches: a new experimental model. Am J Neuroradiol 
2012;33:2004–9.
 10 Rouchaud A, Ramana C, Brinjikji W, et al. Wall Apposition is a key factor for Aneurysm 
occlusion after flow diversion: a histologic evaluation in 41 rabbits. Am J Neuroradiol 
2016:2087–91.
 11 Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary arterial thrombus by 
optical coherence tomography. Am J Cardiol 2006;97:1713–7.
 12 Bezerra hg, Costa MA, guagliumi g, et al. Intracoronary optical coherence 
tomography: a comprehensive review clinical and research applications. JACC 
Cardiovasc Interv 2009;2:1035–46.
 13 lopes DK, Johnson AK. Evaluation of cerebral artery perforators and the pipeline 
embolization device using optical coherence tomography. J Neurointerv Surg 
2012;4:291–4.
 14 van der Marel K, gounis MJ, Weaver JP, et al. grading of regional apposition 
after flow-diverter treatment (gRAFT): a comparative evaluation of VasoCT and 
intravascular OCT. J Neurointerv Surg 2016;8:847–52.
 15 lin lM, Colby gP, Jiang B, et al. Intra-DIC (distal intracranial catheter) deployment of 
the Pipeline embolization device: a novel rescue strategy for failed device expansion. J 
Neurointerv Surg 2016;8:840–6.
 16 Buyukkaya R, Kocaeli h, Yildirim n, et al. Treatment of complex intracranial aneurysms 
using flow-diverting Silk® stents. An analysis of 32 consecutive patients. Interv 
Neuroradiol 2014;20:729–35.
 17 Kühn Al, Wakhloo AK, gounis MJ, et al. Use of self-expanding stents for better 
intracranial flow diverter wall apposition. Interv Neuroradiol 2017;23:129–36.
 18 Daou B, Starke RM, Chalouhi n, et al. P2Y12 reaction units: effect on hemorrhagic 
and thromboembolic complications in patients with cerebral aneurysms treated with 
the pipeline embolization device. Neurosurgery 2016;78:27–33.
 19 Delgado Almandoz JE, Crandall BM, Scholz JM, et al. Pre-procedure P2Y12 reaction 
units value predicts perioperative thromboembolic and hemorrhagic complications 
in patients with cerebral aneurysms treated with the pipeline embolization device. J 
Neurointerv Surg 2013;5 Suppl 3:iii3–10.
 20 Delgado Almandoz JE, Crandall BM, Scholz JM, et al. last-recorded P2Y12 
reaction units value is strongly associated with thromboembolic and hemorrhagic 
complications occurring up to 6 months after treatment in patients with cerebral 
aneurysms treated with the pipeline embolization device.  Am J Neuroradiol 
2014;35:128–35.
group.bmj.com on September 20, 2017 - Published by http://jnis.bmj.com/Downloaded from 
6 Marosfoi M, et al. J NeuroIntervent Surg 2017;0:1–6. doi:10.1136/neurintsurg-2017-013175
Basic science
 21 Collet JP, Cuisset T, Rangé g, et al. Bedside monitoring to adjust antiplatelet therapy 
for coronary stenting. N Engl J Med 2012;367:2100–9.
 22 Brasiliense lB, Stanley MA, grewal SS, et al. Silent ischemic events after pipeline 
embolization device: a prospective evaluation with MR diffusion-weighted imaging. J 
Neurointerv Surg 2016;8:1136–9.
 23 Brinjikji W, lanzino g, Cloft hJ, et al. Risk factors for ischemic complications following 
pipeline embolization device treatment of intracranial aneurysms: results from the 
intrePED study. AJNR Am J Neuroradiol  
2016;37:1673–8.
 24 herbert JM, Dol F, Bernat A, et al. The antiaggregating and antithrombotic activity 
of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. 
Thromb Haemost 1998;80:512–8.
 25 Meyer DM, Compton P, Eastwood JA, et al. Antiplatelet loading improves behavioral 
outcome in a rabbit model of stroke. Stroke  
2013;44:3246–8.
 26 Zhang h, lauver DA, hollenberg PF. CYP-independent inhibition of platelet 
aggregation in rabbits by a mixed disulfide conjugate of clopidogrel. Thromb Haemost 
2014;112:1304–11.
 27 Zhang h, lauver DA, Wang h, et al. Significant improvement of antithrombotic 
responses to clopidogrel by use of a novel conjugate as revealed in an arterial model 
of thrombosis. J Pharmacol Exp Ther 2016;359:11–17.
 28 Zhou X, Kurowski S, Wu W, et al. A rabbit model of cerebral microembolic signals 
for translational research: preclinical validation for aspirin and clopidogrel. J Thromb 
Haemost 2016;14:1855–66.
group.bmj.com on September 20, 2017 - Published by http://jnis.bmj.com/Downloaded from 
diverters
phosphorilcholine surface modified flow 
Acute thrombus formation on
Gounis, Srinivasan Vedantham and Ajit S Puri
Olivia W Brooks, Takamisu Tamura, John M Wainwright, Matthew J 
Miklos Marosfoi, Frederic Clarencon, Erin T Langan, Robert M King,
 published online July 8, 2017J NeuroIntervent Surg 
 5
http://jnis.bmj.com/content/early/2017/07/07/neurintsurg-2017-01317





This article cites 25 articles, 13 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections





To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on September 20, 2017 - Published by http://jnis.bmj.com/Downloaded from 
